BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

612

Figures (1-7)

Tables (1-4)

Sum=789

Publishing Process of This Article

Item

Count

Browse

Download

Sum=113

Nov 15, 2024 (publication date) through Jan 2, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4436-4455
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4436

Table 1 Screening TOP 10 gene by different algorithms of cytohubba

DMNC: Density of maximum neighborhood component; MNC: Maximum neighborhood component.

Citation: Li SL, Wang PY, Jia YP, Zhang ZX, He HY, Chen PY, Liu X, Liu B, Lu L, Fu WH. BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer. World J Gastrointest Oncol 2024; 16(11): 4436-4455
URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4436.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4436